BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Pan J, Qian Y, Weiser P, Zhou X, Lu H, Studelska DR, Zhang L. Glycosaminoglycans and activated contact system in cancer patient plasmas. Prog Mol Biol Transl Sci 2010;93:473-95. [PMID: 20807657 DOI: 10.1016/S1877-1173(10)93020-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dong ZZ, Yao DF, Zhang CG, Qian J, Li SS, Bian YZ, Qiu LW. Glypican-3 expression and its correlation with clinicopathological parameters in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(30): 3113-3117 [DOI: 10.11569/wcjd.v17.i30.3113] [Reference Citation Analysis]
3 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
4 Luo FB, Zhang KH. Advances in the relationship between glypican-3 and primary hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 155-159 [DOI: 10.11569/wcjd.v18.i2.155] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Lin CW, Mars WM, Paranjpe S, Donthamsetty S, Bhave VS, Kang LI, Orr A, Bowen WC, Bell AW, Michalopoulos GK. Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice. Hepatology. 2011;54:620-630. [PMID: 21574168 DOI: 10.1002/hep.24417] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
6 Boswell S, Sharif S, Alisa A, Pereira SP, Williams R, Behboudi S. Induction of latency-associated peptide (transforming growth factor-β(1)) expression on CD4+ T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-α production in a transforming growth factor-β-dependent manner. Immunology 2011;133:278-87. [PMID: 21426338 DOI: 10.1111/j.1365-2567.2011.03425.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
7 Sun S, Lee NP, Poon RT, Fan ST, He QY, Lau GK, Luk JM. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int 2007;27:1021-38. [PMID: 17845530 DOI: 10.1111/j.1478-3231.2007.01533.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
8 Boswell S, Pathan AA, Pereira SP, Williams R, Behboudi S. Induction of CD152 (CTLA-4) and LAP (TGF-β1) in human Foxp3- CD4+ CD25- T cells modulates TLR-4 induced TNF-α production. Immunobiology 2013;218:427-34. [PMID: 22749982 DOI: 10.1016/j.imbio.2012.05.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ma RJ, Wang SH, Qin SN, Wang XB, Li GF, Li M, Xu WW. Preparation and characterization of monoclonal antibody against glypican-3. Hybridoma (Larchmt) 2012;31:455-61. [PMID: 23244326 DOI: 10.1089/hyb.2012.0030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Abdul-Al HM, Makhlouf HR, Wang G, Goodman ZD. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209-212. [PMID: 17949778 DOI: 10.1016/j.humpath.2007.06.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]